| Features: |
| Treatment of disease with radiation, especially by selective irradiation with x-rays or other ionizing radiation and by ingestion of radioisotopes. Radiosensitizer Atorvaqone, (mitochondria inhibitor) decrease O2 consumption making more O2 available as a radiosensitizer. -Hypoxia (low oxygen levels) within tumors is a major cause of resistance to radiotherapy |
| Source: |
| Type: |
C-Reactive Protein (CRP) is a protein produced by the liver in response to inflammation in the body.C-reactive protein is an acute-phase reactant synthesized by the liver in response to IL-6–driven inflammation. In oncology, it serves as a host-response biomarker, not a tumor marker. An elevated CRP integrates multiple cancer-relevant processes: -Tumor-associated inflammation and necrosis -Cytokine signaling (especially IL-6) -Infection or treatment-related tissue injury -Cachexia and systemic catabolism Because it aggregates these signals, CRP is a powerful global severity indicator. Prognosis (Primary Use) -Higher baseline CRP correlates with shorter overall survival across many cancers. -Rising CRP often precedes clinical decline. Treatment Tolerance & Risk -Elevated CRP predicts poor chemotherapy tolerance, higher complication rates, and inferior immunotherapy outcomes in several settings. |
| 7481- | H2, | Rad, | Clinical Efficacy of Hydrogen Therapy on Acute Radiation Enteritis and Inflammatory Response in Patients with Cervical Cancer Undergoing Concurrent Chemoradiation Therapy |
| - | Trial, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:201 Target#:884 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid